Asuragen
In Brief This Week: Bio-Techne, Dante Labs, Metagenomi, Applied DNA Sciences, Caris Life Sciences
News items for the week of April 5, 2021.
Bio-Techne expects the acquisition will provide it with a basis to build out its IVD presence, given Asuragen's diagnostic tests and regulatory expertise.
Bio-Techne to Acquire Molecular Diagnostics Firm Asuragen for up to $320M
Bio-Techne said Asuragen's headquarters in Austin, Texas includes a scalable 50,000-square-foot manufacturing facility and CLIA-certified laboratory.
Pacific Biosciences, Asuragen Collaborate on Clinical Assays
Asuragen will develop assays for PacBio's long-read next-generation sequencing systems, with an initial focus on developing a carrier screening assay.
Asuragen Receives CE Mark for Spinal Muscular Atrophy Assay
The test can help diagnose spinal muscular atrophy and identify carriers without symptoms who may be at risk of passing the disease to their children.
Nov 13, 2018
Health Canada Approves Two BCR-ABL Tests
Sep 7, 2018
Jul 25, 2016
Asuragen BCR-ABL Kit Granted FDA Premarket Clearance
Jun 11, 2015
Asuragen BCR-ABL Assay Receives CE Mark
Dec 10, 2014
Additional Members Join UK Cancer Consortium
Dec 5, 2014